LifeMD (LFMDP) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Consolidated revenue increased by 13% year-over-year to $60.2 million.

Telehealth Revenue: Grew 18% to $47.3 million.

Adjusted EBITDA: Increased by 30% to $5.1 million; telehealth adjusted EBITDA was $2.9 million.

Net Loss: GAAP net loss attributable to common stockholders was $4.6 million ($0.10 per share), an improvement from a loss of $5.4 million ($0.13 per share) in Q3 2024.

Gross Margin: Overall gross margin was 88%, down 290 basis points due to revenue mix; telehealth gross margin was 86%.

Subscriber Growth: Active telehealth subscribers increased by 14% year-over-year to over 310,000.

2Strategic Updates and Business Highlights

RexMD Growth: Added approximately 10,000 net new subscribers, driven primarily by the men's health segment, particularly erectile dysfunction (ED) medications.

Women's and Behavioral Health Initiatives: Significant progress made in developing offerings in these verticals, with potential for substantial revenue growth.

Regulatory Approval: Secured approval for a nonsterile 503-A compounding pharmacy, enhancing the ability to produce personalized medications and improve economics.

Divestiture: Successfully divested majority interest in WorkSimpli, strengthening the balance sheet and focusing on core telehealth and pharmacy operations.

Collaborations: Continued partnerships with Novo Nordisk and Eli Lilly to offer branded GLP-1 medications at reduced prices, with plans to launch oral Wegovy expected in early 2026.

3Forward Guidance and Outlook

Q4 2025 Revenue Guidance: Expected in the range of $45 million to $46 million; adjusted EBITDA projected between $3 million and $4 million.

Full Year 2025 Guidance: Anticipated revenue of $192 million to $193 million, representing a 24% growth year-over-year, with adjusted EBITDA expected to be $13.5 million to $14.5 million, a 254% increase from 2024.

Long-Term Vision: Focus on scaling weight management, women's health, and behavioral health offerings, alongside launching a unified LifeMD platform and marketplace.

4Bad News, Challenges, or Points of Concern

Competitive Pressures: Intense competition from low-cost compounded GLP-1 therapies has created pricing pressure, impacting the weight management category.

Gross Margin Decline: The shift towards branded products has contributed to a decline in gross margins, with expectations of continued mild erosion due to business mix.

Insurance Enablement Delays: While insurance coverage is a strategic priority, the rollout has been slower than anticipated, potentially limiting patient acquisition and revenue growth.

Market Dynamics: The competitive landscape for GLP-1 medications is rapidly evolving, with many new entrants offering aggressive pricing, complicating LifeMD's market positioning.

5Notable Q&A Insights

Product Mix: More than 50% of revenue still comes from weight management, with a noted decline in subscriber growth attributed to market dynamics.

Insurance Coverage Impact: A significant percentage of patients drop off due to lack of insurance coverage; the introduction of Medicare coverage for these medications in 2026 is expected to enhance revenue.

Retention and Differentiation: LifeMD's comprehensive service offerings, including personalized care and a robust pharmacy, are seen as key differentiators against competitors like Amazon and Costco.

Oral GLP-1 Medications: Anticipated launch of oral Wegovy is expected to significantly expand the market, with potential demand increase estimated at 25% to 50%. This summary encapsulates LifeMD's performance and strategic direction as of Q3 2025, highlighting both achievements and challenges as the company prepares for future growth.